Referenser till artikeln "Ortomolekylär behandling av depression, ångest och beteendestörningar"
Raymond J. Pataracchia, naturläkare

1. Delgado PL, Moreno, FA. "Role of norepinephrine in depression." J Clin Psychiatry. 2000; 61(Suppl 1): 5-12.
2. Shelton RC. "The molecular neurobiology of depression." Psychiatr Clin North Am. <javascript:AL_get(this,%20'jour',%20'Psychiatr%20Clin%20North%20Am.');> 2007 Mar; 30(1): 1-11.
3. Herrmann W, Lorenzl S, Obeid R. " [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations]." Fortschr Neurol Psychiatr. 2007 Sep; 75(9): 515-27. (abstract only)
4. Herrmann W, Obeid R. Review: "Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid." Clin Chem Lab Med. 2007 Sep 24. (abstract only)
5. Bottiglieri T. "Homocysteine and folate metabolism in depression." Prog Neuropsychopharmacol Biol Psychiatry. 2005 Sep; 29(7): 1103-12.
6. Coppen A, Bolander-Gouaille C. "Treatment of depression: time to consider folic acid and vitamin B12." J Psychopharmacol. 2005 Jan; 19(1): 59-65.
7. Gilbody S, Lewis S, Lightfoot T. "Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review." Am J Epidemiol. 2007 Jan 1; 165(1): 1-13.
8. Parnetti L, Bottiglieri T, Lowenthal D. "Role of homocysteine in age-related vascular and non-vascular diseases." Aging (Milan, Italy). 1997 Aug; 9(4): 241-257.
9. Kelly G. "Peripheral Metabolism of Thyroid Hormones: A Review." Alternative Medicine Review, 2000; 5(4): 306-333.
10. Aschner M, Cherian MG, Klaassen CD, et al. "Metallothioneins in brain – the role in physiology and pathology." Toxicol Appl Pharmacol, 1997; 142(2): 229-242.
11. Stanley PC, Wakwe VC. "Toxic trace metals in the mentally ill patients." Niger Postgrad Med J. 2002 Dec; 9(4): 199-204.
12. Jones CE, Underwood CK, Coulson EJ, et al. "Copper induced oxidation of serotonin: analysis of products and toxicity." J Neurochem, 2007 Aug; 102(4): 1035-1043.
13. Kitchen I. "Lead toxicity and alterations in opioid systems." Neurotoxicology, 1993 Summer-Fall; 14(2-3): 115-124.
14. Cai L, Li XK, Song Y, Cherian MG. "Essentiality, toxicology and chelation therapy of zinc and copper." Curr Med Chem, 2005; 12(23): 2753-2763.
15. Goyer RA. "Nutrition and metal toxicity." Am J Clin Nutr, 1995 Mar; 61(3 Suppl): 646S-650S.
16. Heinrich TW, Grahm G. "Hypothyroidism Presenting as Psychosis: Myxedema Madness Revisited." Prim Care Companion J Clin Psychiatry, 2003 Dec; 5(6): 260-266.
17. Mello AA, Mello MF, Carpenter LL, et al. "Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis." Rev Bras Psiquiatr, 2003 Oct; 25(4): 231-238.
18. Abdullatif HD, Ashraf AP. "Reversible subclinical hypothyroidism in the presence of adrenal insufficiency." Endocr Pract, 2006 Sep-Oct; 12(5): 572.
19. Candrina R, Giustina G. "Addison's disease and corticosteroid-reversible hypothyroidism." J Endocrinol Invest, 1987 Oct; 10(5): 523-526.
20. Contreras F, Menchon JM, Urretavizcaya M, et al. "Hormonal differences between psychotic and non-psychotic melancholic depression." J Affect Disord, 2007 Jun; 100(1-3): 65-73.
21. Bauer M, London ED, Silverman DH, et al. "Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging." Pharmacopsychiatry, 2003 Nov; 36 Suppl 3: S215-S221.
22. Jackson IM. "The thyroid axis and depression." Thyroid, 1998 Oct; 8(10): 951-956.
23. Haggerty JJ, Stern RA, Mason GA, et al. "Subclinical hypothyroidism: a modifiable risk factor for depression?" American Journal of Psychiatry, 1993; 150: 508-510.
24. Monzani F, Del Guerra P, Caraccio N, et al. "Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment." Clinical Investigator, 1993; 71: 367-371.
25. Toffe RJ, Levitt AJ. "Major depression and subclinical (grade 2) hypothyroidism." Psychoneuroendocrinology, 1992; 17: 215-221.
26. McGaffee J, Barnes MA, Lippmann S. "Psychiatric presentations of hypothyroidism." Am Fam Physician, 1981 May; 23(5): 129-133.
28. Haddow JE, Palomaki GE, Allan WC, et al. "Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child." N Engl J Med, 1999 Aug 19; 341(8): 549-555.
29. Brouwer A, Morse DC, Lans MC, et al. "Interactions of persistent environmental organohalogens with the thyroid hormone system: mechanisms and possible consequences for animal and human health." Toxicol Ind Health, 1998 Jan-Apr; 14(1-2): 59-84.
30. Westphal SA. "Unusual presentations of hypothyroidism." Am J Med Sci, 1997 Nov; 314(5): 333-337.
31. Heitman B, Irizarry A. "Hypothyroidism: common complaints, perplexing diagnosis." Nurse Pract, 1995 Mar; 20(3): 54-60.
32. Shafer RB, Prentiss RA, Bond JH. "Gastrointestinal transit in thyroid disease." Gastroenterology, 1984 May; 86(5 Pt 1): 852-855.
33. Oppenheimer JH, Braverman LE, Toft A, et al. "A therapeutic controversy. Thyroid hormone treatment: when and what?" J Clin Endocrinol Metab, 1995; 80(10): 2873-2883.
34. Hatterer JA, Herbert J, Hidaka C, et al. "CSF transthyretin in patients with depression." Am J Psychiatry, 1993; 150(5): 813-815.
35. Schreiber G. "The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis." J Endocrinol, 2002; 175(1): 61-73.
36. Sullivan GM, Mann JJ, Oquendo MA, et al. "Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function." Biol Psychiatry, 2006; 60(5): 500-506.
37. Sullivan GM, Hatterer JA, Herbert J, et al. "Low levels of transthyretin in the CSF of depressed patients." Am J Psychiatry, 1999; 156(5): 710-715.
38. Wan C, Yang Y, Li H, et al. "Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients." J Proteome Res, 2006; 5(11): 3213-3216.
39. Huang JT, Leweke FM, Oxley D, et al. "Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis." PLoS Med, 2006; 3(11): e428.
40. Zheng W, Lu YM, Lu GY, et al. "Transthyretin, thyroxine, and retinol-binding protein in human cerebrospinal fluid: effect of lead exposure." Toxicol Sci, 2001; 61(1): 107-114.
41. Zheng W, Blaner WS, Zhao Q. "Inhibition by lead of production and secretion of transthyretin in the choroid plexus: its relation to thyroxine transport at blood-CSF barrier." Toxicol Appl Pharmacol, 1999; 155(1): 24-31.
42. Visser TJ, Leonard JL, Kaplan MM, et al. "Kinetic evidence suggesting two mechanisms for iodothyronine 5'-deiodination in rat cerebral cortex." Proc Natl Acad Sci USA, 1982; 79(16): 5080-5084.
43. Barnes BO, Galton L. Hypothyroidism: The Unsuspected Illness. New York, NY. Harper & Row. 1976.
44. Michel V, Peinnequin A, Alonso A, et al. "Decreased heat tolerance is associated with hypothalamo-pituitary-adrenocortical axis impairment." Neuroscience, 2007 Jun 29; 147(2): 522-531.
45. Lum SM, Nicoloff JT, Spencer CA, et al. "Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man." J Clin Invest, 1984 Feb; 73(2): 570-575.
46. Bourre JM. "Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients." J Nutr Health Aging, 2006 Sep-Oct; 10(5): 377-385.
47. Cuajungco MP, Lees GJ. "Zinc metabolism in the brain: relevance to human neurodegenerative disorders." Neurobiol Dis, 1997; 4(3-4): 137-169.
48. Johnson S. "Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson's disease?" Med Hypotheses, 2001; 56(5): 641-645.
49. Sahley, BJ. "Nutrition and Mental Illness. " MMRC Health Educator Reports, 2006: 1-2.
50. Marz RB. Medical Nutrition from Marz. Portland, OR. Omni-Press. 1997.
51. Pfeiffer CC, Braverman ER. "Zinc, the brain and behavior." Biol Psychiatry, 1982; 17(4): 513-532.
52. Noseworthy MD, Bray TM. "Zinc deficiency exacerbates loss in blood-brain barrier integrity induced by hyperoxia measured by dynamic MRI." Proc Soc Exp Biol Med, 2000; 223(2): 175-182.
53. Levine J, Stahl Z, Sela BA, et al. "Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia." Biol Psychiatry, 2006; 60 (3): 265-269.
54. Wenzel K-G. "Orthomolecular Treatment for Mental Health: The Roles of Hypoglycemia, Pyrroluria and Histamine Disturbances." 2000 Apr. Nutritional Medicine Today 29th Annual Conference. Vancouver, BC.
55. Jackson JA, Riordan HD, Neathery S, et al. "Case from the Center: Urinary Pyrrole in Health and Disease." J Orthomol Med, 1997; 12(2): 96-98.
56. Edelman E. Natural Healing for Schizophrenia: A Compendium of Nutritional Methods. Eugene, OR. Borage Books. 1996.
57. Pfeiffer CC. Mental and Elemental Nutrients. New Canaan, CN. Keats Publishing. 1975.
58. Sohler A, Beck R, Noval JJ. "Mauve factor re-identified as 2,4-dimethyl-3-ethylpyrrole and its sedative effect on the CNS." Nature, 1970; 228(278): 1318-1320.
59. Hoffer A. Orthomolecular Medicine for Physicians. New Canaan, CT. Keats Publishing. 1989.
60. Cox D, Gonder-Frederick L, McCall A, et al. "The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes." Int J Clin Pract Suppl, 2002 Jul; 129: 20-26.
61. Mitrakou A, Ryan C, Veneman T, et al. "Hierarchy of glycemic thresholds for counter regulatory hormone secretion, symptoms, and cerebral dysfunction." Am J Physiol, 1991 Jan; 260(1 Pt 1): E67-E74.
62. Greenwood CE, Young SN. "Dietary fat intake and the brain: a developing frontier in biological psychiatry." J Psychiatry Neurosci, 2001 May; 26(3): 182–184.
63. McNamara RK, Carlson SE. "Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology." Prostaglandins Leukot Essent Fatty Acids, 2006 Oct-Nov; 75(4-5): 329-349.
64. Kidd PM. "Bipolar disorder and cell membrane dysfunction. Progress toward integrative management." Altern Med Rev, 2004 Jun; 9(2): 107-135.
65. Ranjekar PK, Hinge A, Hegde MV, et al. "Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients." Psychiatry Res, 2003 Dec 1; 121(2): 109-122.
66. Hardman G, Hart G. "Dietary advice based on food-specific IgG results." Nutrition & Food Science, 2007; 37(1): 16-23.
67. Jackson JA, Neathery S, Kirby R: Hidden Food Sensitivities. "A Common Cause of Many Illnesses." J Orthomol Med, 2007; 22(1): 27-30.
68. Crowe SE, Perdue MH. "Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology." Gastroenterology, 1992 Sep; 103(3): 1075-1095.
69. Hall K. "Allergy of the nervous system: a review." Annals of Allergy, 1976 Jan; 36(1): 49-64.
70. Takahashi M, Fukunaga H, Kaneto H et al. "Behavioral and pharmacological studies on gluten exorphin A5, a newly isolated bioactive food protein fragment, in mice." Jpn J Pharmacol, 2000 Nov; 84(3): 259-265.
71. King DS. "Psychological and behavioral effects of food and chemical exposure in sensitive individuals." Nutr Health, 1984; 3(3): 137-151.
72. Atkinson W, Sheldon TA, Shaath N, et al. "Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial." Gut, 2004 Oct; 53(10): 1459-1464.
73. Stone, I. The healing factor: vitamin C against disease. New York. Grosset and Dunlap. 1972.
74. Prousky, JE. "Supplemental niacinamide mitigates anxiety symptoms: three case reports." J Orthomol Med, 2005; 20(3): 167-178.
75. Pitche PT. "Service de dermatologie." Sante, 2005 Jul-Sep; 15(3): 205-208. (abstract only)
76. Hoffer A. "Vitamin B-3 Dependency: Chronic Pellagra." Townsend Letter for Doctors & Patients. 2000 Oct; 207: 66-73.